Corvus Pharmaceuticals
CRVSCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel product candidates that target proteins essential to immune cell maturation and function.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel product candidates that target proteins essential to immune cell maturation and function. The company leverages its expertise in T cell signaling to create therapies for immune-mediated diseases, inflammatory conditions, and various cancers. Its primary value proposition lies in its proprietary approach to immune system rebalancing, specifically through the selective inhibition of the ITK enzyme.
A clinical-stage innovator utilizing a proprietary mechanism of action for ITK inhibition, currently advancing a registrational Phase 3 trial in rare lymphomas.
Questions, answered.
- What is Corvus Pharmaceuticals's market cap?
- Corvus Pharmaceuticals (CRVS) has a market capitalization of $1.1B and trades on NASDAQ.
- Who are Corvus Pharmaceuticals's competitors?
- Corvus Pharmaceuticals's key competitors include Regeneron Pharmaceuticals, AbbVie, Eli Lilly, and others. These companies compete in similar markets and product categories.
- Who does Corvus Pharmaceuticals partner with?
- Corvus Pharmaceuticals's notable partners include Kidney Cancer Research Consortium, Bristol-Myers Squibb, Sanofi.
- Where is Corvus Pharmaceuticals headquartered?
- Corvus Pharmaceuticals is headquartered in United States of America and employs approximately 28 people. It has been publicly traded since 2016.